Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LNZ101 and LNZ100 in Chinese Subjects with Presbyopia
NCT06270030Phase 1Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aceclidine and brimonidine tartrate + sodium hyaluronate in presbyopia (3 arms), sponsored by CORXEL Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 4 more. Started Mar 2024; status: completed.
02
Drugs
aceclidinebrimonidine tartrate + sodium hyaluronate
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT06270030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270030.